CoChat

Exercise-Induced Muscle–Fat Crosstalk: Molecular Mediators and Their Pharmacological Modulation for the Maintenance of Metabolic Flexibility in Aging

Open access

The DOI matches its Crossref record; 145 of the 146 references it cites were found in a registry or an index; 123 of the 190 sources its claims cite were checked for support.

Abstract

Regular physical activity induces a dynamic crosstalk between skeletal muscle and adipose tissue, modulating the key molecular pathways that underlie metabolic flexibility, mitochondrial function, and inflammation. This review highlights the role of myokines and adipokines-particularly IL-6, irisin, leptin, and adiponectin-in orchestrating muscle-adipose tissue communication during exercise. Exercise stimulates AMPK, PGC-1α, and SIRT1 signaling, promoting mitochondrial biogenesis, fatty acid oxidation, and autophagy, while also regulating muscle hypertrophy through the PI3K/Akt/mTOR and Wnt/β-catenin pathways. Simultaneously, adipose-derived factors like leptin and adiponectin modulate skeletal muscle metabolism via JAK/STAT3 and AdipoR1-mediated AMPK activation. Additionally, emerging exercise mimetics such as the mitochondrial-derived peptide MOTS-c and myostatin inhibitors are highlighted for their roles in increasing muscle mass, the browning of white adipose tissue, and improving systemic metabolic function. The review also addresses the role of anti-inflammatory compounds, including omega-3 polyunsaturated fatty acids and low-dose aspirin, in mitigating NF-κB and IL-6 signaling to protect mitochondrial health. The resulting metabolic flexibility, defined as the ability to efficiently switch between lipid and glucose oxidation, is enhanced through repeated exercise, counteracting age- and disease-related mitochondrial and functional decline. Together, these adaptations demonstrate the importance of inter-tissue signaling in maintaining energy homeostasis and preventing sarcopenia, obesity, and insulin resistance. Finally, here we propose a stratified treatment algorithm based on common age-related comorbidities, offering a framework for precision-based interventions that may offer a promising strategy to preserve metabolic plasticity and delay the age-associated decline in cardiometabolic health.

Overview

CoChat Summary

TL;DR

This narrative review synthesizes molecular crosstalk between skeletal muscle and adipose tissue during exercise, focusing on IL-6, irisin, leptin, adiponectin, and AMPK–PGC-1α–SIRT1 signaling in aging. It proposes pharmacological exercise mimetics and a comorbidity-stratified treatment algorithm to preserve metabolic flexibility when exercise capacity is limited.

Key findings

  • Exercise-induced myokines/adipokines regulate metabolic flexibility: IL-6 has a half-life of approximately 5 min and can increase up to 100-fold during physical activity; 5 h at 40% VO2 max increased IL-6 19-fold, and recombinant human IL-6 raised circulating IL-6 to approximately 40 pg/mL versus approximately 1 pg/mL baseline, with a twofold increase in systemic fatty acid oxidation after 60 min.
  • PGC-1α is central to mitochondrial adaptation: whole-body PGC-1α knockout mice after acute exercise showed a 40% reduction in mitochondrial content and a 25% decline in running performance, while trained individuals displayed mitochondrial adaptation independent of age.
  • Irisin promotes white adipose tissue browning via UCP1 and p38 MAPK/ERK signaling; myostatin inhibits muscle growth and WAT browning through the AMPK–PGC-1α–FNDC5 axis, and male myostatin-deficient mice fed a high-fat diet showed a 40-fold reduction in TNF-α and improved insulin sensitivity.
  • Pharmacological modulators—metformin, berberine, PPAR agonists, resveratrol, NAD+ precursors, MOTS-c, myostatin inhibitors, omega-3 fatty acids, and low-dose aspirin—converge on AMPK, PGC-1α, SIRT1, PPARs, and NF-κB; the review proposes a stratified algorithm for aging T2DM patients with limited exercise capacity.

Methods

  • Narrative review; no systematic search protocol or primary data are reported.
  • Synthesizes preclinical models (e.g., PGC-1α KO, Mstn−/−, high-fat-diet mice), human exercise studies, and meta-analyses, including 72 controlled trials on leptin and 25 studies with 262 acute-exercise and 377 chronic-exercise participants.
  • Main analysis is a narrative mechanistic synthesis and proposal of a stratified pharmacological algorithm (Table 1) for aging individuals with T2DM and common comorbidities.

Limitations

  • Stated: much evidence is based on preclinical models or short-term clinical studies, limiting extrapolation to older adults with multiple comorbidities; long-term safety and efficacy of exercise mimetics require further validation in diverse aging populations.
  • Stated: interindividual variability in response to exercise and pharmacological interventions is poorly understood and may be influenced by genetic background, microbiome composition, sex differences, and epigenetic factors; the translational gap remains substantial.
  • Evident: as a narrative review, it lacks systematic search and quality appraisal; the proposed stratified treatment algorithm is conceptual and not prospectively validated in clinical trials.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/ph18081222

Cites

145 of 145 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Metabolic effect of the myokine IL-6 released during exercise. Muscle activity leads to lactic acid formation in skeletal muscle because of glycolysis, along with the depletion of intramuscular glycogen stores. Owing to the intensification of mitochondrial oxidative metabolism, there is an increased production of reactive oxygen species (ROS) and oxidative stress. The red arrows indicate the main promoters of IL-6 release from the muscle during exercise. The release of IL-6 into the circulation promotes the mobilization of fatty acids from adipose tissue by activating enzymes such as hormone-sensitive lipase (HSL), adipose triglyceride lipase (ATGL), and α-ketoglutarate dehydrogenase (AOX), while simultaneously inhibiting fatty acid synthesis via the inhibition of fatty acid synthase (FAS). In the liver, IL-6 stimulates gluconeogenesis through activation of the gp130/JAK/STAT3 signaling pathway and activation of key gluconeogenic enzymes, including phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G-6-P-ase). In skeletal muscle, IL-6-induced activation of AMPK facilitates GLUT-4 translocation and glucose uptake into muscle cells through an insulin-independent mechanism, while also promoting β-oxidation of fatty acids, particularly short-chain fatty acids, for aerobic ATP production. ↑ up arrows mean increase and ↓ down arrows mean decrease. This image was created using BioRender (https://BioRender.com/n4xejkf, accessed on 18 August 2025).
Figure 1 Metabolic effect of the myokine IL-6 released during exercise. Muscle activity leads to lactic acid formation in skeletal muscle because of glycolysis, along with the depletion of intramuscular glycogen stores. Owing to the intensification of mitochondrial oxidative metabolism, there is an increased production of reactive oxygen species (ROS) and oxidative stress. The red arrows indicate the main promoters of IL-6 release from the muscle during exercise. The release of IL-6 into the circulation promotes the mobilization of fatty acids from adipose tissue by activating enzymes such as hormone-sensitive lipase (HSL), adipose triglyceride lipase (ATGL), and α-ketoglutarate dehydrogenase (AOX), while simultaneously inhibiting fatty acid synthesis via the inhibition of fatty acid synthase (FAS). In the liver, IL-6 stimulates gluconeogenesis through activation of the gp130/JAK/STAT3 signaling pathway and activation of key gluconeogenic enzymes, including phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G-6-P-ase). In skeletal muscle, IL-6-induced activation of AMPK facilitates GLUT-4 translocation and glucose uptake into muscle cells through an insulin-independent mechanism, while also promoting β-oxidation of fatty acids, particularly short-chain fatty acids, for aerobic ATP production. ↑ up arrows mean increase and ↓ down arrows mean decrease. This image was created using BioRender (https://BioRender.com/n4xejkf, accessed on 18 August 2025).CC BY · PubMed Central
Figure 2 Exercise-induced irisin release promotes browning of white adipose tissue. Physical activity activates PGC-1α expression in skeletal muscle, leading to the cleavage of FNDC5 into the circulating myokine irisin. Irisin acts on white adipocytes to upregulate UCP1, a key thermogenic marker, and initiates mitochondrial biogenesis. This signaling cascade results in the browning of WAT, characterized by increased mitochondrial concentration and enhanced energy dissipation as heat. (PGC-1α—peroxisome proliferator-activated receptor gamma coactivator-1 alpha, FNDC5—fibronectin type III domain-containing protein 5, UCP1—uncoupling protein 1, CPT1—carnitine palmitoyltransferase 1, FAs—fatty acids, ACOX1—acyl-CoA oxidase 1, SIRT1—sirtuin 1, p38 MAPK—p38 mitogen-activated protein kinase, ERK—extracellular signal-regulated kinase, ↑ up arrows mean increase). This image was created using BioRender. (https://BioRender.com/67zf659, accessed on 18 August 2025).
Figure 2 Exercise-induced irisin release promotes browning of white adipose tissue. Physical activity activates PGC-1α expression in skeletal muscle, leading to the cleavage of FNDC5 into the circulating myokine irisin. Irisin acts on white adipocytes to upregulate UCP1, a key thermogenic marker, and initiates mitochondrial biogenesis. This signaling cascade results in the browning of WAT, characterized by increased mitochondrial concentration and enhanced energy dissipation as heat. (PGC-1α—peroxisome proliferator-activated receptor gamma coactivator-1 alpha, FNDC5—fibronectin type III domain-containing protein 5, UCP1—uncoupling protein 1, CPT1—carnitine palmitoyltransferase 1, FAs—fatty acids, ACOX1—acyl-CoA oxidase 1, SIRT1—sirtuin 1, p38 MAPK—p38 mitogen-activated protein kinase, ERK—extracellular signal-regulated kinase, ↑ up arrows mean increase). This image was created using BioRender. (https://BioRender.com/67zf659, accessed on 18 August 2025).CC BY · PubMed Central
Figure 3 Leptin and adiponectin signaling pathways in skeletal muscle and liver. This schematic illustrates the peripheral actions of the adipokines leptin and adiponectin on skeletal muscle and the liver in the context of physical activity and metabolic regulation. Leptin, which is secreted by adipose tissue, binds to its long-form LepRb in skeletal muscle and the liver. In skeletal muscle, leptin activates the JAK/STAT3, PGC-1α, and AMPK signaling pathways, promoting mitochondrial biogenesis, glucose uptake, and fatty acid oxidation. Leptin, through binding to hepatic LepRb receptors, can inhibit gluconeogenesis and improve lipid metabolism under resting and postprandial conditions. However, during acute physical exercise, this effect is counterbalanced by stress hormones and myokines such as IL-6, which stimulate gluconeogenesis to ensure the necessary ATP supply for active skeletal muscle. Adiponectin, which acts primarily through its receptor AdipoR1 in muscle, stimulates AMPK and PPARα signaling, enhancing glucose uptake, fatty acid oxidation, and mitochondrial function. (LepRb—leptin receptor isoform b, JAK—Janus kinase, STAT3—signal transducer and activator of transcription 3, PGC-1α—peroxisome proliferator-activated receptor gamma coactivator 1-alpha, AMPK—AMP-activated protein kinase, IL-6—interleukin-6, ATPadenosine triphosphate, AdipoR1—adiponectin receptor 1, PPARα—peroxisome proliferator-activated receptor alpha, FAs—fatty acids, ↑ up arrows mean increase). This image was created using BioRender (https://BioRender.com/d3aik7f, accessed on 18 August 2025).
Figure 3 Leptin and adiponectin signaling pathways in skeletal muscle and liver. This schematic illustrates the peripheral actions of the adipokines leptin and adiponectin on skeletal muscle and the liver in the context of physical activity and metabolic regulation. Leptin, which is secreted by adipose tissue, binds to its long-form LepRb in skeletal muscle and the liver. In skeletal muscle, leptin activates the JAK/STAT3, PGC-1α, and AMPK signaling pathways, promoting mitochondrial biogenesis, glucose uptake, and fatty acid oxidation. Leptin, through binding to hepatic LepRb receptors, can inhibit gluconeogenesis and improve lipid metabolism under resting and postprandial conditions. However, during acute physical exercise, this effect is counterbalanced by stress hormones and myokines such as IL-6, which stimulate gluconeogenesis to ensure the necessary ATP supply for active skeletal muscle. Adiponectin, which acts primarily through its receptor AdipoR1 in muscle, stimulates AMPK and PPARα signaling, enhancing glucose uptake, fatty acid oxidation, and mitochondrial function. (LepRb—leptin receptor isoform b, JAK—Janus kinase, STAT3—signal transducer and activator of transcription 3, PGC-1α—peroxisome proliferator-activated receptor gamma coactivator 1-alpha, AMPK—AMP-activated protein kinase, IL-6—interleukin-6, ATPadenosine triphosphate, AdipoR1—adiponectin receptor 1, PPARα—peroxisome proliferator-activated receptor alpha, FAs—fatty acids, ↑ up arrows mean increase). This image was created using BioRender (https://BioRender.com/d3aik7f, accessed on 18 August 2025).CC BY · PubMed Central
Figure 4 Molecular mechanisms through which exercise regulates skeletal muscle metabolism, mitochondrial quality, and adipose tissue remodeling. Acute exercise increases oxygen consumption and hypoxic stress, leading to elevated ROS and an increased AMP/ATP ratio, which activates AMPK. Activated AMPK phosphorylates and upregulates PGC-1α, promoting mitochondrial quality control via biogenesis, mitophagy, fusion, and fission. PGC-1α also induces FNDC5 expression, resulting in the secretion of irisin, a myokine that stimulates UCP1 expression and browning in white adipose tissue. In parallel, exercise promotes glucose uptake through GLUT4 translocation to the plasma membrane. Chronic exercise activates the PI3K–Akt–mTORC1 pathway by inhibiting the TSC and activating Rheb, thereby supporting protein synthesis and muscle hypertrophy. Resistance training also suppresses C1q-induced Wnt signaling, which otherwise contributes to muscle atrophy and fibrosis. In the absence of Wnt, β-catenin is degraded via a complex that includes GSK-3β, Axin, APC, and CK1α. Wnt activation inactivates this complex, allowing β-catenin to enter the nucleus, bind TCF/LEF, and drive the transcription of genes involved in muscle growth and repair. Together, these pathways contribute to increased metabolic flexibility, improved mitochondrial function, and the prevention of sarcopenia. (AMPK—AMP-activated protein kinase, PGC-1α—Peroxisome proliferator-activated receptor gamma coactivator 1-alpha, FNDC5—Fibronectin type III domain-containing protein 5, UCP1—Uncoupling protein 1, GLUT4—Glucose transporter type 4, ROS—Reactive oxygen species, PI3K—Phosphoinositide 3-kinase, Akt—Protein kinase B, TSC—Tuberous sclerosis complex, Rheb—Ras homolog enriched in brain, mTORC1—Mechanistic target of rapamycin complex 1, BAT—Brown adipose tissue, C1q—Complement component 1q, GSK-3β—Glycogen Synthase Kinase-3 Beta, APC—Adenomatous Polyposis Coli, CK1α—Casein Kinase 1 alpha, TCF—T-cell Factor, LEF—Lymphoid Enhancer-binding Factor, ↑ up arrows mean increase). This image was created using BioRender (https://biorender.com/yhzyxwv, accessed on 18 August 2025).
Figure 4 Molecular mechanisms through which exercise regulates skeletal muscle metabolism, mitochondrial quality, and adipose tissue remodeling. Acute exercise increases oxygen consumption and hypoxic stress, leading to elevated ROS and an increased AMP/ATP ratio, which activates AMPK. Activated AMPK phosphorylates and upregulates PGC-1α, promoting mitochondrial quality control via biogenesis, mitophagy, fusion, and fission. PGC-1α also induces FNDC5 expression, resulting in the secretion of irisin, a myokine that stimulates UCP1 expression and browning in white adipose tissue. In parallel, exercise promotes glucose uptake through GLUT4 translocation to the plasma membrane. Chronic exercise activates the PI3K–Akt–mTORC1 pathway by inhibiting the TSC and activating Rheb, thereby supporting protein synthesis and muscle hypertrophy. Resistance training also suppresses C1q-induced Wnt signaling, which otherwise contributes to muscle atrophy and fibrosis. In the absence of Wnt, β-catenin is degraded via a complex that includes GSK-3β, Axin, APC, and CK1α. Wnt activation inactivates this complex, allowing β-catenin to enter the nucleus, bind TCF/LEF, and drive the transcription of genes involved in muscle growth and repair. Together, these pathways contribute to increased metabolic flexibility, improved mitochondrial function, and the prevention of sarcopenia. (AMPK—AMP-activated protein kinase, PGC-1α—Peroxisome proliferator-activated receptor gamma coactivator 1-alpha, FNDC5—Fibronectin type III domain-containing protein 5, UCP1—Uncoupling protein 1, GLUT4—Glucose transporter type 4, ROS—Reactive oxygen species, PI3K—Phosphoinositide 3-kinase, Akt—Protein kinase B, TSC—Tuberous sclerosis complex, Rheb—Ras homolog enriched in brain, mTORC1—Mechanistic target of rapamycin complex 1, BAT—Brown adipose tissue, C1q—Complement component 1q, GSK-3β—Glycogen Synthase Kinase-3 Beta, APC—Adenomatous Polyposis Coli, CK1α—Casein Kinase 1 alpha, TCF—T-cell Factor, LEF—Lymphoid Enhancer-binding Factor, ↑ up arrows mean increase). This image was created using BioRender (https://biorender.com/yhzyxwv, accessed on 18 August 2025).CC BY · PubMed Central
Figure 5 The coordinated effects of leptin and adiponectin on skeletal muscle metabolism, mitochondrial function, and inflammation. This figure illustrates the regulation of skeletal muscle physiology by leptin and adiponectin. Leptin exerts anabolic and metabolic effects through the activation of the PI3K/Akt pathway via IGF-1, resulting in the suppression of myostatin, increased expression of PCNA and cyclin D, and downregulation of FoxO3a, which reduces atrophy-related gene expression. Leptin also enhances PGC-1α expression and increases glucose uptake by promoting insulin sensitivity and GLUT4 translocation. Additionally, leptin stimulates sympathetic activation (via β-AR), which leads to AMPK activation and downstream inhibition of ACC, reducing malonyl-CoA levels and facilitating fatty acid oxidation. Adiponectin binds to AdipoR1, triggering Ca2+ influx and activation of the CaMKK–APPL–LKB1 pathway, which also activates AMPK. This in turn enhances FA transport (FAT/CD36), improves the oxidative stress response, and upregulates PGC-1α, promoting mitochondrial biogenesis and inhibiting FoxO-mediated proteolysis. Through SIRT1, adiponectin further modulates FoxO activity, suppressing proteolytic gene expression. In parallel, adiponectin promotes macrophage polarization toward the anti-inflammatory M2 phenotype, increasing IL-10 secretion and contributing to a protective, anti-inflammatory muscle microenvironment. (IGF-1—Insulin-like growth factor-1, PI3K—Phosphoinositide 3-kinase, Akt—Protein kinase B, PCNA—Proliferating cell nuclear antigen, FoxO—Forkhead box O, AMPK—AMP-activated protein kinase, ACC—Acetyl-CoA carboxylase, FAT/CD36—Fatty acid translocase/Cluster of differentiation 36, PGC-1α—Peroxisome proliferator-activated receptor gamma coactivator-1 alpha, SIRT1—Sirtuin 1, APPL—Adaptor protein containing PH domain, PTB domain and leucine zipper motif, LKB1—Liver kinase B1, CaMKK—Ca2+/calmodulin-dependent protein kinase kinase, IL-10—Interleukin-10, M1/M2—Pro-inflammatory (M1) and anti-inflammatory (M2) macrophage phenotypes, β AR—Beta-adrenergic receptor, ↑ up arrows mean increase and ↓ down arrows mean decrease). This image was created using BioRender (https://BioRender.com/r0klswn, accessed on August 2025).
Figure 5 The coordinated effects of leptin and adiponectin on skeletal muscle metabolism, mitochondrial function, and inflammation. This figure illustrates the regulation of skeletal muscle physiology by leptin and adiponectin. Leptin exerts anabolic and metabolic effects through the activation of the PI3K/Akt pathway via IGF-1, resulting in the suppression of myostatin, increased expression of PCNA and cyclin D, and downregulation of FoxO3a, which reduces atrophy-related gene expression. Leptin also enhances PGC-1α expression and increases glucose uptake by promoting insulin sensitivity and GLUT4 translocation. Additionally, leptin stimulates sympathetic activation (via β-AR), which leads to AMPK activation and downstream inhibition of ACC, reducing malonyl-CoA levels and facilitating fatty acid oxidation. Adiponectin binds to AdipoR1, triggering Ca2+ influx and activation of the CaMKK–APPL–LKB1 pathway, which also activates AMPK. This in turn enhances FA transport (FAT/CD36), improves the oxidative stress response, and upregulates PGC-1α, promoting mitochondrial biogenesis and inhibiting FoxO-mediated proteolysis. Through SIRT1, adiponectin further modulates FoxO activity, suppressing proteolytic gene expression. In parallel, adiponectin promotes macrophage polarization toward the anti-inflammatory M2 phenotype, increasing IL-10 secretion and contributing to a protective, anti-inflammatory muscle microenvironment. (IGF-1—Insulin-like growth factor-1, PI3K—Phosphoinositide 3-kinase, Akt—Protein kinase B, PCNA—Proliferating cell nuclear antigen, FoxO—Forkhead box O, AMPK—AMP-activated protein kinase, ACC—Acetyl-CoA carboxylase, FAT/CD36—Fatty acid translocase/Cluster of differentiation 36, PGC-1α—Peroxisome proliferator-activated receptor gamma coactivator-1 alpha, SIRT1—Sirtuin 1, APPL—Adaptor protein containing PH domain, PTB domain and leucine zipper motif, LKB1—Liver kinase B1, CaMKK—Ca2+/calmodulin-dependent protein kinase kinase, IL-10—Interleukin-10, M1/M2—Pro-inflammatory (M1) and anti-inflammatory (M2) macrophage phenotypes, β AR—Beta-adrenergic receptor, ↑ up arrows mean increase and ↓ down arrows mean decrease). This image was created using BioRender (https://BioRender.com/r0klswn, accessed on August 2025).CC BY · PubMed Central
Figure 6 Pharmacological targeting of convergent signaling pathways to enhance metabolic flexibility in aging: an integrated mechanistic model. This figure presents a conceptual framework summarizing how diverse pharmacological agents modulate key molecular pathways to preserve metabolic flexibility, particularly in older individuals with limited physical activity. Metabolic flexibility, the capacity to efficiently switch between glucose and lipid utilization in response to energy demands, is governed by the dynamic interplay of mitochondrial function, nutrient sensing, muscle–fat crosstalk, and low-grade inflammation. The diagram shows how different drug classes exert complementary and sometimes overlapping effects on these regulatory nodes. Metformin and berberine activate AMPK, a central metabolic sensor that enhances glucose uptake, FA oxidation, and mitochondrial biogenesis. PPAR agonists, such as pioglitazone (PPAR-γ) and GW501516 (PPAR-δ, experimental), further promote insulin sensitivity, lipid transport, and oxidative metabolism by upregulating genes involved in mitochondrial function. The SIRT1/PGC-1α axis, activated by compounds such as resveratrol and NAD+ precursors (e.g., NR, NMN), promotes mitochondrial health, oxidative phosphorylation, and cellular resilience to stress. Emerging agents that mimic exercise-induced signaling include myostatin inhibitors, which reduce muscle catabolism and enhance myokine secretion (e.g., irisin) leading to white adipose tissue browning and improved thermogenic capacity. Similarly, MOTS-c, a mitochondrial-derived peptide, functions as a potent AMPK activator, improving glucose metabolism and lipid oxidation. In parallel, anti-inflammatory agents such as omega-3 polyunsaturated FAs and low-dose aspirin mitigate chronic low-grade inflammation by attenuating NF-κB and IL-6 signaling, indirectly supporting insulin action and mitochondrial function (AMPK—AMP-activated protein kinase, IL-6—interleukin-6, NF-κB—nuclear factor-κB, MOTS-c—mitochondrial open reading frame of the 12S rRNA type-c, FAs—fatty acids, SIRT1—sirtuin, PGC-1α—peroxisome proliferator-activated receptor gamma coactivator 1-alpha, NAD+—nicotinamide adenine dinucleotide, NR—nicotinamide riboside, NMN—nicotinamide mononucleotide, PPAR—peroxisome proliferator-activated receptor, ↑ up arrows mean increase and ↓ down arrows mean decrease).
Figure 6 Pharmacological targeting of convergent signaling pathways to enhance metabolic flexibility in aging: an integrated mechanistic model. This figure presents a conceptual framework summarizing how diverse pharmacological agents modulate key molecular pathways to preserve metabolic flexibility, particularly in older individuals with limited physical activity. Metabolic flexibility, the capacity to efficiently switch between glucose and lipid utilization in response to energy demands, is governed by the dynamic interplay of mitochondrial function, nutrient sensing, muscle–fat crosstalk, and low-grade inflammation. The diagram shows how different drug classes exert complementary and sometimes overlapping effects on these regulatory nodes. Metformin and berberine activate AMPK, a central metabolic sensor that enhances glucose uptake, FA oxidation, and mitochondrial biogenesis. PPAR agonists, such as pioglitazone (PPAR-γ) and GW501516 (PPAR-δ, experimental), further promote insulin sensitivity, lipid transport, and oxidative metabolism by upregulating genes involved in mitochondrial function. The SIRT1/PGC-1α axis, activated by compounds such as resveratrol and NAD+ precursors (e.g., NR, NMN), promotes mitochondrial health, oxidative phosphorylation, and cellular resilience to stress. Emerging agents that mimic exercise-induced signaling include myostatin inhibitors, which reduce muscle catabolism and enhance myokine secretion (e.g., irisin) leading to white adipose tissue browning and improved thermogenic capacity. Similarly, MOTS-c, a mitochondrial-derived peptide, functions as a potent AMPK activator, improving glucose metabolism and lipid oxidation. In parallel, anti-inflammatory agents such as omega-3 polyunsaturated FAs and low-dose aspirin mitigate chronic low-grade inflammation by attenuating NF-κB and IL-6 signaling, indirectly supporting insulin action and mitochondrial function (AMPK—AMP-activated protein kinase, IL-6—interleukin-6, NF-κB—nuclear factor-κB, MOTS-c—mitochondrial open reading frame of the 12S rRNA type-c, FAs—fatty acids, SIRT1—sirtuin, PGC-1α—peroxisome proliferator-activated receptor gamma coactivator 1-alpha, NAD+—nicotinamide adenine dinucleotide, NR—nicotinamide riboside, NMN—nicotinamide mononucleotide, PPAR—peroxisome proliferator-activated receptor, ↑ up arrows mean increase and ↓ down arrows mean decrease).CC BY · PubMed Central

Verification

Claims the paper makes

80 Valid · 37 Not valid · 62 Not checked · 43 Own results and interpretations

97 more claims · 47 with their cited sources checked

Create a free account to see all 222 claims and to verify the 7 references still open.

See all claims — free account
  • It may state two separate claims as one. 112
  • Probably not a substantial claim. 13

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Cited by

See all 44

Metadata

Authors
Tero-Vescan, A., Degens, H., Matsakas, A., Ștefănescu, R., Ősz, B. E., & Slevin, M.
Affiliations
  • Universitatea de Medicină, Farmacie, Științe și Tehnologie „George Emil Palade” din Târgu Mureș (RO)
  • Manchester Metropolitan University (GB)
Corresponding author
Slevin, Mark
Venue
Pharmaceuticals
Publisher
MDPI AG
Published
2025-08-19
Volume
18
Issue
8
Pages
1222
ISSN
1424-8247 (ISSN-L)
OpenAlex
W4413326218
Cited by
44
References
146
Citations by year
2026: 41 · 2025: 3
FWCI
5.76
Type
journal article
Language
en
Open access
Locations
  • Pharmaceuticals (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • e-space (Manchester Metropolitan University) (acceptedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
  • Health Sciences › Medicine › Physiology (medical) › Exercise and Physiological Responses
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Keywords
physical activity, metabolic flexibility, aging, myokines, adipokines, interleukin-6, irisin, leptin, adiponectin, AMPK signaling, PGC-1α, SIRT1, mitochondrial biogenesis, fatty acid oxidation, autophagy, muscle hypertrophy, Wnt/β-catenin signaling, PI3K/AKT/mTOR pathway, AdipoR1, MOTS-c, myostatin inhibitors, brown adipose tissue, omega-3 polyunsaturated fatty acids, low-dose aspirin, NF-κB, sarcopenia, insulin resistance, obesity, precision medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.